Sonoma Pharmaceuticals and EMC Pharma Announce Collaboration to Co-market an Expanded Eye Care Product Line
Sonoma Pharmaceuticals (NASDAQ:SNOA) and EMC Pharma have announced a co-marketing agreement to launch and sell an expanded prescription and OTC eye care product line. The collaboration includes:
1. EMC Pharma gaining rights to sell OTC Ocucyn
2. Sonoma gaining rights to sell prescription Acuicyn
3. Introduction of new design and packaging for Ocucyn
4. Presentation of the expanded product line at the American Academy of Ophthalmology's annual meeting in Chicago, October 18-21, 2024
Both products are based on Sonoma's patented Microcyn technology using stabilized hypochlorous acid (HOCl). This partnership aims to increase sales of both OTC and prescription eye care products by coordinating marketing efforts and expanding market reach.
Sonoma Pharmaceuticals (NASDAQ:SNOA) ed EMC Pharma hanno annunciato un accordo di co-marketing per lanciare e vendere una linea ampliata di prodotti per la cura degli occhi, sia su prescrizione che da banco. La collaborazione include:
1. EMC Pharma che ottiene i diritti per vendere OTC Ocucyn
2. Sonoma che ottiene i diritti per vendere la prescrizione Acuicyn
3. Introduzione di un nuovo design e packaging per Ocucyn
4. Presentazione della linea di prodotti ampliata al convegno annuale dell'American Academy of Ophthalmology a Chicago, dal 18 al 21 ottobre 2024
Entrambi i prodotti sono basati sulla tecnologia brevettata Microcyn di Sonoma, che utilizza acido ipocloroso stabilizzato (HOCl). Questa partnership mira ad aumentare le vendite di prodotti per la cura degli occhi sia OTC che su prescrizione, coordinando gli sforzi di marketing e ampliando la portata sul mercato.
Sonoma Pharmaceuticals (NASDAQ:SNOA) y EMC Pharma han anunciado un acuerdo de co-marketing para lanzar y vender una línea ampliada de productos para el cuidado ocular, tanto con receta como de venta libre. La colaboración incluye:
1. EMC Pharma adquiriendo derechos para vender OTC Ocucyn
2. Sonoma adquiriendo derechos para vender la receta Acuicyn
3. Introducción de un nuevo diseño y empaque para Ocucyn
4. Presentación de la línea de productos ampliada en el congreso anual de la American Academy of Ophthalmology en Chicago, del 18 al 21 de octubre de 2024
Ambos productos se basan en la tecnología patentada Microcyn de Sonoma, que utiliza ácido hipocloroso estabilizado (HOCl). Esta asociación tiene como objetivo aumentar las ventas de productos para el cuidado ocular, tanto OTC como con receta, coordinando esfuerzos de marketing y ampliando el alcance en el mercado.
소노마 제약(SNASDAQ:SNOA)와 EMC 제약이 처방전과 비처방 안과 제품 라인을 확장하기 위한 공동 마케팅 계약을 발표했습니다. 협력의 내용은 다음과 같습니다:
1. EMC 제약이 OTC Ocucyn 판매 권리를 획득
2. 소노마가 처방전 Acuicyn 판매 권리를 획득
3. Ocucyn의 새로운 디자인과 포장 소개
4. 2024년 10월 18일부터 21일까지 시카고에서 열리는 미국 안과학회 연례 회의에서 확장된 제품 라인 발표
두 제품 모두 소노마의 특허 받은 Microcyn 기술을 기반으로 하며, 안정화된 차아염소산(HOCl)을 사용합니다. 이 파트너십은 마케팅 노력을 조정하고 시장 도달 범위를 확장하여 OTC 및 처방 안과 제품의 판매를 증가시키는 것을 목표로 합니다.
Sonoma Pharmaceuticals (NASDAQ:SNOA) et EMC Pharma ont annoncé un accord de co-marketing pour lancer et vendre une gamme élargie de produits de soins oculaires, tant sur ordonnance qu'en vente libre. La collaboration comprend :
1. EMC Pharma obtenant les droits de vendre OTC Ocucyn
2. Sonoma obtenant les droits de vendre Acuicyn sur ordonnance
3. Introduction d'un nouveau design et emballage pour Ocucyn
4. Présentation de la gamme de produits élargie lors de la réunion annuelle de l'American Academy of Ophthalmology à Chicago, du 18 au 21 octobre 2024
Les deux produits sont basés sur la technologie brevetée Microcyn de Sonoma, utilisant de l'acide hypochloreux stabilisé (HOCl). Ce partenariat vise à augmenter les ventes de produits de soins oculaires, tant OTC que sur ordonnance, en coordonnant les efforts marketing et en élargissant la portée sur le marché.
Sonoma Pharmaceuticals (NASDAQ:SNOA) und EMC Pharma haben eine Co-Marketing-Vereinbarung bekannt gegeben, um eine erweiterte Produktlinie für die Augenpflege, sowohl verschreibungspflichtig als auch rezeptfrei, zu lancieren und zu verkaufen. Die Zusammenarbeit umfasst:
1. EMC Pharma erwirbt das Recht, OTC Ocucyn zu verkaufen
2. Sonoma erwirbt das Recht, das verschreibungspflichtige Produkt Acuicyn zu verkaufen
3. Einführung eines neuen Designs und Verpackung für Ocucyn
4. Präsentation der erweiterten Produktlinie auf dem jährlichen Treffen der American Academy of Ophthalmology in Chicago vom 18. bis 21. Oktober 2024
Beide Produkte basieren auf der patentierten Microcyn-Technologie von Sonoma, die stabilisierte hypochlorige Säure (HOCl) verwendet. Diese Partnerschaft zielt darauf ab, die Verkäufe von OTC- und rezeptpflichtigen Augenpflegeprodukten durch koordinierte Marketinganstrengungen und die Erweiterung der Marktreichweite zu steigern.
- Expansion of product offerings in the eye care market
- New co-marketing agreement potentially increasing sales and market reach
- Introduction of improved packaging for Ocucyn, enhancing user convenience
- Opportunity to present expanded product line at major industry event (AAO conference)
- None.
This collaboration between Sonoma Pharmaceuticals and EMC Pharma represents a strategic move in the eye care market. By expanding their product line and improving packaging, they're positioning themselves for potential market share growth. The co-marketing agreement allows both companies to leverage each other's strengths and distribution channels, which could lead to increased sales and brand visibility.
The introduction of Ocucyn as an OTC product alongside the prescription-strength Acuicyn creates a comprehensive eye care offering. This dual-approach strategy caters to both consumer and professional markets, potentially expanding their customer base. The timing of the launch at the American Academy of Ophthalmology's annual meeting is strategic, providing maximum exposure to key industry professionals.
While this news is positive for both companies, investors should monitor actual sales performance and market reception of the new product line to gauge its true impact on Sonoma's financial health.
The collaboration highlights the growing importance of hypochlorous acid (HOCl) in ophthalmology. Sonoma's Microcyn technology, which forms the basis of these products, has shown promise in managing various ocular conditions. The expansion into both OTC and prescription markets with Ocucyn and Acuicyn respectively demonstrates a comprehensive approach to eye care.
The products' ability to address issues like dry eye, blepharitis and meibomian gland dysfunction taps into significant market needs. With the rising prevalence of digital eye strain and age-related eye conditions, these solutions could see increasing demand. The gentle yet effective nature of HOCl makes it an attractive option for daily eye hygiene and post-procedural care.
However, the efficacy and long-term safety of these products in various ophthalmic applications will be important for sustained market success. Investors should keep an eye on any forthcoming clinical data or professional endorsements that could further validate these products' effectiveness.
BOULDER, CO / ACCESSWIRE / September 11, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, in partnership with EMC Pharma, LLC, today announced they have entered into a co-marketing agreement to launch and sell an expanded prescription and OTC eye care product line. The new eye care line will also feature refreshed design and improved packaging for Ocucyn® Eyelid & Eyelash Cleanser. The full line will be introduced at the American Academy of Ophthalmology's annual meeting in Chicago, October 18-21, 2024.
Sonoma and EMC Pharma entered into a distribution agreement in 2021, granting EMC Pharma the exclusive right to manage, market and distribute Sonoma's HOCl-based prescription dermatology and eye care products in the United States. Pursuant to an addendum to this agreement, EMC Pharma will now additionally have the right to sell over-the-counter Ocucyn, and Sonoma will have the right to sell Acuicyn® Eyelid & Eyelash Cleanser, a prescription product marketed to ophthalmologists.
In addition, Sonoma is introducing a new design and consumer-friendly packaging for Ocucyn, featuring a one-piece dispense mechanism, which allows for more convenient use.
Ocucyn and Acuicyn are hypochlorous acid-based solutions designed to gently cleanse the area surrounding the eye, removing dirt, oil and debris along with microorganisms such as bacteria, fungi and viruses, using the power of Microcyn technology. The over-the-counter formulation of Ocucyn is ideal for daily eye hygiene and to relieve itch and irritation. Ocucyn is also used by ophthalmologists before and after eye exams, treatments or operations, or by skin care professionals following medspa treatments or any cosmetic procedure around the eyes. Acuicyn provides a prescription strength formula that ophthalmologists can utilize in their practice or prescribe to their patients to manage symptoms of chronic eye conditions such as dry eye, contact lens intolerance, blepharitis and meibomian gland dysfunction.
The co-marketing of these products will allow Sonoma and EMC Pharma to provide their customers with additional options for eye care and expand the market reach for each product. Acuicyn and the newly redesigned Ocuyn will be presented by Sonoma and EMC Pharma at the American Academy of Ophthalmology's annual meeting in Chicago, October 18-21, 2024.
"Eye care has been an area of growth for EMC and we are pleased to expand our partnership with Sonoma, and to expand our product offerings," said Eric Bailey, Chief Executive Officer of EMC Pharma. "Ocucyn will provide an over-the-counter option for our existing customers in addition to attracting new eye care customers in our distribution channels which include many government entities."
"Our partnership with EMC Pharma has been a success for both companies, and we are excited to open up new channels for both Sonoma and EMC with this co-marketing agreement. Both companies have invested in marketing eye care products and by coordinating our efforts, we expect to increase sales of both OTC and prescription eye care," commented Amy Trombly, CEO of Sonoma. "We look forward to presenting this expanded product line at the AAO conference in October."
Ocucyn is available to consumers through our website and on Amazon. Products with new packaging can be ordered now for October delivery. For more information or to order Ocucyn Eyelid & Eyelash Cleanser, visit our website at https://otc.sonomapharma.com/products/ocucyn-eyelid-and-eyelash-cleanser or contact our customer service department at 720-452-9690 or customerservice@sonomapharma.com.
About EMC Pharma, LLC
EMC Pharma is a pharmaceutical manufacturing and distribution company focused on sales, marketing and distribution of prescription pharmaceuticals within a full spectrum of therapeutic areas and dosage forms, and is committed to bringing innovative, cost-effective medications to its stakeholders. EMC Pharma leverages its global network of developers and manufacturing partners to create an expanding portfolio of pharmaceutical products commercialized for the US market. Further information about EMC Pharma can be found at https://www.emcpharma.com.
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Sonoma's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. Sonoma's products are sold either directly or via partners in 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact busdev@sonomapharma.com.
Forward-Looking Statements
Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "develop," "anticipate," "expect" and "expand," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company's cash needs, fund further development, as well as uncertainties relative to the COVID-19 pandemic and economic development, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.
Sonoma Pharmaceuticals™, Microcyn®, Ocucyn® and Acuicyn® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.
Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.
ir@sonomapharma.com
Website: www.sonomapharma.com
Follow us on LinkedIn: https://www.linkedin.com/company/sonoma-pharmaceuticals
Follow us on Instagram: https://www.instagram.com/sonomapharma_us/
Follow us on Facebook: https://www.facebook.com/sonomapharma/
SOURCE: Sonoma Pharmaceuticals, Inc.
View the original press release on accesswire.com
FAQ
What is the new co-marketing agreement between Sonoma Pharmaceuticals (SNOA) and EMC Pharma?
When will Sonoma Pharmaceuticals (SNOA) introduce its new eye care product line?
What improvements has Sonoma Pharmaceuticals (SNOA) made to Ocucyn?
How can consumers purchase Ocucyn from Sonoma Pharmaceuticals (SNOA)?
